PepTech Corporation is a biotechnology company that develops and commercializes peptide-based therapeutics. The company's proprietary platform technology enables the design and development of novel peptides that can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. PepTech's lead product candidate, PT-001, is a peptide-based cancer vaccine that is currently in Phase 1 clinical trials. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.